BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-2173 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-2173\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07354932-11089@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:SHR-2173: Phase 2 readout est. (NCT07354932)
DESCRIPTION:SHR-2173\, phase 2.\nStudy: A Study of SHR-2173 in Participants
  With Primary IgA Nephropathy\nEstimated primary completion: April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/shr-2173#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07354932
URL:https://assetmemo.bio/drug/shr-2173#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229742-11089@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SHR-2173: Phase 2 readout est. (NCT07229742)
DESCRIPTION:SHR-2173\, phase 2\, Lupus Nephritis.\nStudy: A Phase II Clinic
 al Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment
  of Patients With Active Lupus Nephritis\nEstimated primary completion: Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-2173#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0722974
 2
URL:https://assetmemo.bio/drug/shr-2173#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07289763-11089@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:SHR-2173: Phase 2 readout est. (NCT07289763)
DESCRIPTION:SHR-2173\, phase 2.\nStudy: Phase II Randomized\, Open-label\, 
 Multicenter Clinical Study Evaluating the Safety\, Efficacy\, Pharmacokine
 tics\, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary
  Membranous Nephropathy\nEstimated primary completion: August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/shr-2173#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07289763
URL:https://assetmemo.bio/drug/shr-2173#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622342-11089@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SHR-2173: Phase 2 readout est. (NCT07622342)
DESCRIPTION:SHR-2173\, phase 2.\nStudy: A Phase II Study of SHR-2173 Inject
 ion in Patients With Myasthenia Gravis\nEstimated primary completion: Sept
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-2173#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0762
 2342
URL:https://assetmemo.bio/drug/shr-2173#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299422-11089@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:SHR-2173: Phase 2 readout est. (NCT07299422)
DESCRIPTION:SHR-2173\, phase 2.\nStudy: A Study of SHR-2173 in Participants
  With Systemic Lupus Erythematosus\nEstimated primary completion: March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/shr-2173#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07299422
URL:https://assetmemo.bio/drug/shr-2173#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
